Latest Conference Articles

At SLEEP 2025, Malhotra emphasized the need for weight loss to resolve obesity hypoventilation syndrome and highlighted limitations of current therapies.

At SLEEP 2025, Malhotra shared updates on diagnosing and managing OHS, including the role of bicarbonate, PAP use, and weight loss.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’

At SLEEP 2025, HCPLive spoke to Strollo about the phase 3 SynAIRgy trial which evaluated AD109, a first-in-class, once-daily oral neuromuscular modulator, for OSA.

At SLEEP 2025, Cassiere discussed how pulse oximetry inaccuracies among patients with darker skin tones may lead to underdiagnosis or misclassification of sleep apnea severity.

At SLEEP 2025, Lillis discussed how wearable data revealed disruptions in sleep consolidation up to 13 weeks postpartum despite total sleep duration nearing pre-pregnancy levels.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

At SLEEP 2025, Walia discussed findings showing Hispanic individuals may experience more severe cases of sleep disordered breathing compared to the non-Hispanic group.

At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.

At SLEEP 2025, Winkelman discussed the AASM’s updated guidelines urging clinicians to transition patients with RLS off dopamine agonists due to augmentation risks.

At SLEEP 2025, Kancherla highlights diagnostic dilemmas, treatment gaps, and the need for pediatric criteria when managing obstructive sleep apnea in teens.

At SLEEP 2025, Kancherla emphasized the importance of using pediatric criteria to manage OSA in adolescents, warning that adult standards may overlook key developmental factors.

This interview at RAD 2025 highlights a session on dose flexibility in adult patients with atopic dermatitis, presented by Tejesh Patel, MD.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

These data suggest that smoking history did not impact rates of malignancy, MACE, and VTE among those with atopic dermatitis treated with upadacitinib.

In this Q&A interview at RAD 2025, Tiffany Mayo, MD, highlights the biggest takeaways from her talk on complex cases in atopic dermatitis and hair loss.

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

At SLEEP 2025, Axsome Therapeutics presented phase 3 ENCORE and SYMPHONY data showing AXS-12 reduced cataplexy attacks and improved daytime functioning in narcolepsy.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

At SLEEP 2025, Fung discussed how combining a masked taper, CBT-I, and a nightly dose-tracking diary helped older adults achieve long-term benzodiazepine discontinuation.

At SLEEP 2025, Fung shared that masked taper plus CBT-I led to higher benzodiazepine discontinuation and improved sleep in older adults.

In this RAD 2025 interview, Paller highlights her team’s findings on disease and family burden of topic dermatitis in children.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

In this interview, Yosipovitch touches on the topics featured in his RAD 2025 presentation ‘Managing Itch,’ specifically regarding patients with atopic dermatitis.

At SLEEP 2025, Danny Eckert, PhD, discussed new drug therapies for OSA, including tirzepatide, AD109, potassium channel blockers, and acetazolamide.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.